News & Media

Press Releases

CURRENT | 2008 | 2007 | 2006 | 2005 | 2004

06/16/2010
 Trius Therapeutics Obtains Special Protocol Assessment with FDA for Phase 3 Study
of Torezolid Phosphate
05/19/2010
 Trius Therapeutics Awarded U.S. Department of Defense Contract to Develop Novel Antibiotics
03/29/2010
 Trius Announces Results from Phase 1 Clinical Trial Of Intravenous Torezolid Phosphate
03/01/2010
 Trius Therapeutics to Conform Protocol for Upcoming Torezolid Phosphate Phase 3 Trial with Newly Released FDA Draft Guidance
11/06/2009
 Trius Therapeutics Files Registration Statement for Proposed Initial Public Offering
09/12/2009
 Trius' Torezolid Antibiotic for the Treatment of Severe Skin Infections Featured at ICAAC Meeting
07/01/2009
 PharmaVOICE selects Dr. Jeff Stein as one of their 100 of the Most Inspiring People.
06/08/2009
 Trius Announces Positive Results from Phase 2 Clinical Trial of Torezolid in Patients with Complicated Skin and Skin Structure Infections
05/18/2009
 Trius Presents New Data on Torezolid Antibiotic for Treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections
05/06/2009
 Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases
04/20/2009
 Trius Appoints Don Batts and Ralph Corey to Clinical Advisory Board
01/26/2009
 Trius Completes Enrollment in Phase 2 Clinical Trial Evaluating Torezolid (Torezolid) in Patients with Complicated Skin and Skin Structure Infections